Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Abstract Objective Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-ce...

全面介紹

書目詳細資料

發表在:	BMC Cancer
Main Authors:	Rui-Lian Chen, Jun Zhao, Xu-Chao Zhang, Na-Na Lou, Hua-Jun Chen, Xue Yang, Jian Su, Zhi Xie, Qing Zhou, Hai-Yan Tu, Wen-Zhao Zhong, Hong-Hong Yan, Wei-Bang Guo, Yi-Long Wu, Jin-Ji Yang
格式:	Article
語言:	英语
出版:	BMC 2018-11-01
主題:	Anaplastic lymphoma kinase Mesenchymal epithelial transition Non-small-cell lung cancer Rearrangement C-Met, overexpression
在線閱讀:	http://link.springer.com/article/10.1186/s12885-018-5078-y